On January 17, 2025, the Biden U.S. Department of Agriculture (USDA) issued an interim final rule with a request for comment ...

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

A 3D model accurately mimicking the blood-brain barrier (BBB) in a laboratory environment has been successfully developed by ...

The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...

The Graduate Aptitude Test-Biotechnology (GAT-B) 2025 application period is now open at exams.nta.ac.in/DBT, according to the ...

The National Testing Agency (NTA) has commenced the registration process for the Graduate Aptitude Test – Biotechnology ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced the closing of a public offering of an ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

That, combined with tight funding in biotech, has led to a flurry of licensing ... It’s in multi-country Phase 3 trials in CML, as well as for two other forms of cancer. Though similar drugs, such as ...

There’s also the possibility that “A Quiet Place 3” could introduce new characters in a different location, still under siege from the same breed of marauding predators from the OG films.